Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.

Whatever the consensus opinion may be, our team at StockStory cuts through the noise by conducting independent analysis to determine a company’s long-term prospects. Keeping that in mind, here are two stocks where you should be greedy instead of fearful and one where the skepticism is well-placed.

One Stock to Sell:

Myriad Genetics (MYGN)

Consensus Price Target: $7.77 (-1.6% implied return)

Founded in 1991 as one of the pioneers in translating genetic discoveries into clinical applications, Myriad Genetics (NASDAQ: MYGN) develops genetic tests that assess disease risk, guide treatment decisions, and provide insights across oncology, women's health, and mental health.

Why Should You Sell MYGN?

1. Muted 5.5% annual revenue growth over the last five years shows its demand lagged behind its healthcare peers
2. Push for growth has led to negative returns on capital, signaling value destruction, and its falling returns suggest its earlier profit pools are drying up
3. Eroding returns on capital from an already low base indicate that management’s recent investments are destroying value

At $7.90 per share, Myriad Genetics trades at 189.8x forward P/E. Read our free research report to see why you should think twice about including MYGN in your portfolio.

Two Stocks to Watch:

ResMed (RMD)

Consensus Price Target: $294.73 (9.2% implied return)

Founded in 1989 to address the then-underdiagnosed condition of sleep apnea, ResMed (NYSE: RMD) develops cloud-connected medical devices and software solutions that treat sleep apnea, COPD, and other respiratory disorders for home and clinical use.

Why Could RMD Be a Winner?

1. Business is well-positioned no matter the global macroeconomic backdrop as its constant currency revenue growth averaged 10.3% over the past two years
2. Additional sales over the last five years increased its profitability as the 14.9% annual growth in its earnings per share outpaced its revenue
3. Free cash flow margin expanded by 12.5 percentage points over the last five years, providing additional flexibility for investments and share buybacks/dividends

ResMed’s stock price of $270 implies a valuation ratio of 25x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free for active Edge members.

JPMorgan Chase (JPM)

Consensus Price Target: $325 (9.1% implied return)

Tracing its roots back to 1799 when its earliest predecessor was founded by Aaron Burr, JPMorgan Chase (NYSE: JPM) is a leading financial services company offering investment banking, consumer banking, commercial banking, and asset management services globally.

Why Is JPM on Our Radar?

1. Unique value proposition resonates with borrowers, as seen in its above-market 11.3% annual net interest income growth over the last five years
2. Share repurchases have amplified shareholder returns as its annual earnings per share growth of 9% exceeded its revenue gains over the last two years
3. Annual tangible book value per share growth of 10.6% over the past five years was outstanding, reflecting strong capital accumulation this cycle

JPMorgan Chase is trading at $298 per share, or 2.4x forward P/B. Is now a good time to buy? See for yourself in our full research report, it’s free for active Edge members.

Stocks We Like Even More

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.